NVX vs TNXP Comparison

NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.